Tumor Regression Grade As Predictor of Adjuvant Therapy Benefits in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• (I) underwent R0 resection with either two-field or three-field lymphadenectomy (II) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (III) had esophageal squamous cell carcinoma pathology.
Locations
Other Locations
China
Fujian Medical University Union Hospital
RECRUITING
Fuzhou
Contact Information
Primary
Maohui Chen
757860733@qq.com
18659181171
Backup
Yizhou Huang
1204382231@qq.com
13959568242
Time Frame
Start Date: 2024-10-01
Estimated Completion Date: 2025-10-10
Participants
Target number of participants: 400
Treatments
Good responders
Good responders (TRG 0-1). The pathologic report of the patient after neoadjuvant combined surgery
Poor responders
Poor responders (TRG 2-3). The pathologic report of the patient after neoadjuvant combined surgery
Related Therapeutic Areas
Sponsors
Collaborators: The First Affiliated Hospital of Xiamen University, Quanzhou First Hospital
Leads: Fujian Medical University Union Hospital